CURRENT
ISSUE
1634

Annual vaccination against influenza A and B viruses is recommended for everyone ≥6 months old without a contraindication.1 Available influenza vaccines for the 2021-2022 season are listed in Table 2.

Vaccination of all eligible persons can reduce the prevalence of influenza illness and symptoms that might be confused with those of COVID-19. Lower-than-usual rates of influenza illness have been observed this season in the Southern Hemisphere, probably because of masking, social distancing, school closures, and travel restrictions.2 According to the CDC, reduced immunity due to low influenza virus activity since March 2020 may...  Continue reading

More from Issue 1634
Previous Issue: 1633      September 20, 2021
Coming Soon
Treatment of Onychomycosis
Bamlanivimab and Etesevimab for Post-Exposure Prophylaxis of COVID-19
Trilaciclib (Cosela) to Prevent Myelosuppression in Small Cell Lung Cancer
Search
Donate
Subscribe
Conversation
Follow us   Twitter LinkedIn YouTube Blog RSS   Email Alerts
Advance Release
ADVANCE
RELEASE

The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance – Boehringer Ingelheim) has been approved by the FDA for a third indication: to reduce the risk of hospitalization for heart failure (HF) and cardiovascular death in patients with heart failure with reduced ejection fraction (HFrEF), with or without type 2 diabetes. The SGLT2 inhibitor dapagliflozin ... Continue reading

 Tweets